GW468816

· Massachusetts General Hospital

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GW468816, covering 2010-12-20 to 2010-12-20. Get the full timeline:

Most recent: Clinical Trial Update: Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking [Phase 2]